Search

Displaying results 6451 - 6460 of 10000 in total
  1. Drug

    Human growth hormone-releasing peptide 3

    go.drugbank.com/drugs/DB19227
    Investigational

    Human growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

  2. Drug

    Citicoline

    go.drugbank.com/drugs/DB12153
    ApprovedInvestigationalWithdrawn

    Citicoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides.

  3. Drug

    Ditazole

    go.drugbank.com/drugs/DB08994
    ApprovedWithdrawn

    Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.

  4. Drug

    Totrombopag

    go.drugbank.com/drugs/DB05930
    Investigational

    used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled bleeding, thus representing a significant problem in

  5. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  6. Drug

    OSI-461

    go.drugbank.com/drugs/DB05415
    Investigational

    OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

  7. Drug

    NCX 701

    go.drugbank.com/drugs/DB05409
    Experimental

    Nitroparacetamol (NCX-701) is a newly synthesized nitric oxide-releasing derivative of paracetamol.

  8. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    Talampanel is a substance that is being studied in the treatment of brain tumors and other brain disorders, such as epilepsy and Parkinson disease. It is a type of AMPA receptor antagonist.

  9. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

  10. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.